R. Visswanathan

The Bioanalysis of Targeted Nanoparticles in Monkey Plasma via LC-MS/MS.

C. Holliman, Z. Gu, Wei Song, 2019, Analytical chemistry.

Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies

S. Yamazaki, P. Vicini, J. Lucas, 2016, Clinical Cancer Research.

Mechanistic Insights on Clearance and Inhibition Discordance between Liver Microsomes and Hepatocytes When Clearance in Liver Microsomes Is Higher than in Hepatocytes.

A. Carlo, J. Cianfrogna, R. Obach, 2020, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor.

X. Mu, J. Bienkowska, Zhou Zhu, 2021, Cancer cell.

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195).

Ping Chen, Hong Shen, M. Pairish, 2020, Journal of medicinal chemistry.

Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer.

J. Lapek, Sherry L. Niessen, M. McTigue, 2021, Journal of medicinal chemistry.

Distribution, Metabolism, and Excretion of Gedatolisib in Healthy Male Volunteers After a Single Intravenous Infusion

B. Houk, L. Kirkovsky, Kyle T. Matschke, 2018, Clinical pharmacology in drug development.

Leveraging model-based study designs and serial micro-sampling techniques to understand the oral pharmacokinetics of the potent LTB4 inhibitor, CP-105696, for mouse pharmacology studies

S. Bagrodia, M. Spilker, V. Fantin, 2017, Xenobiotica; the fate of foreign compounds in biological systems.

Pharmacokinetics of the potent LTB4 Inhibitor, CP-105696, in Male and Female Mice.

S. Bagrodia, M. Spilker, V. Fantin, 2016 .

Leveraging model-based study designs and serial micro-sampling techniques to understand

S. Bagrodia, M. Spilker, V. Fantin, 2016 .